Possible predictive biomarkers for tumor response to mTOR inhibitors, as are explained in glioblastoma, breast and prostate most cancers cells, may be the differential expression of mTOR pathway proteins, PTEN, AKT, and S6.[1] Therefore, this facts is predicated on preclinical assays, depending on in vitro cultured tumor cell lines, which https://steveg297xbf9.blogsumer.com/profile